AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Precision Radiation Oncology Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Thoracic radiotherapy timing and prognostic factors in elderly patients with limited-stage small cell lung cancer

Huan Zhao1,2, Yue Qi2, Lanfang Zhang2, Meng Xing2, Fujun Yang2 ( )
Binzhou Medical University, Yantai, Shandong, China
Key Laboratory of Precision Diagnosis and Treatment in Oncology of Weihai, Department of Oncology, Weihai Municipal Hospital, Weihai, Shandong, China
Show Author Information

Abstract

Objective

This study assessed the outcomes of elderly patients with limited-stage small cell lung cancer (LS-SCLC), which may be linked to the timing of thoracic radiotherapy (TRT) following chemotherapy.

 Methods

Elderly patients (n = 78) with LS-SCLC were divided into three groups depending on the timing of radiotherapy. The patients in the TRT group were stratified into early (TRT after 1–2 cycles of chemotherapy, n = 29), medium-term (TRT after 3–4 cycles of chemotherapy, n = 33), and late (TRT after 5–6 cycles of chemotherapy, n = 16) TRT groups. The overall survival (OS) and progression-free survival (PFS) were assessed and compared.

 Results

The medium-term TRT group demonstrated significantly longer mPFS (20.12 months) and better mOS (35.97 months) than those in the other groups (PFS: P = 0.021;OS: P = 0.035). A pairwise comparison of the three groups revealed that those who received medium-term TRT exhibited significantly improved PFS than the early (mPFS: 20.12 vs. 10.36 mouths, P = 0.018) and late (mPFS: 20.12 vs. 9.17 months, P = 0.016) TRT. The medium-term TRT group demonstrated significantly improved OS than the early TRT (mOS: 35.97 vs. 25.22 months, P = 0.007) but not in comparison with the late TRT (mOS: 35.97 vs. 21.63 months, P = 0.100).

 Conclusion

In elderly patients with LS-SCLC, the addition of TRT after 3–4 cycles of chemotherapy appears to be a viable and potentially beneficial treatment approach.

Keywords

prognosiselderly patientsintensity modulated radiation therapylimited-stage small cell lung cancerradiotherapy timingthoracic radiotherapy

References

1

Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539-4544.
Crossref Google Scholar
2

Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25(35):5570-5577.
Crossref Google Scholar
3

Ganti AKP, Loo BW, Bassetti M, et al. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(12):1441-1464.
Crossref Google Scholar
4

Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10(6):890-895.
Crossref Google Scholar
5

Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327(23):1618-1624.
Crossref Google Scholar
6

Barros JM, Rizzo MM, Chiozza JO, Couñago F. Is there a place for optimizing thoracic radiotherapy in limited-stage small cell lung cancer after twenty years? World J Clin Oncol. 2021;12(1):1-5.
Crossref Google Scholar
7

Takada M, Fukuoka M, Kawahara M, et al. Phase Ⅲ study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol. 2002;20(14):3054-3060.
Crossref Google Scholar
8

Work E, Nielsen OS, Bentzen SM, Fode K, Palshof T. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. J Clin Oncol. 1997;15(9):3030-3037.
Crossref Google Scholar
9

Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993;11(2):336-344.
Crossref Google Scholar
10

Gregor A, Drings P, Burghouts J, et al. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. J Clin Oncol. 1997;15(8):2840-2849.
Crossref Google Scholar
11

Perry MC, Herndon JE 3rd, Eaton WL, Green MR. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. J Clin Oncol. 1998;16(7):2466-2467.
Crossref Google Scholar
12

Skarlos DV, Samantas E, Briassoulis E, et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase Ⅱ study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2001;12(9):1231-1238.
Crossref Google Scholar
13

Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol. 1997;15(3):893-900.
Crossref Google Scholar
14

Yang FJ, Zhao H. Progress in radiotherapy for small-cell lung cancer.Prec Radiat Oncol.2023;7(3):207-217
Crossref Google Scholar
15

Bayman E, Etiz D, Akcay M, Ak G. Timing of thoracic radiotherapy in limited stage small cell lung cancer: results of early versus late irradiation from a single institution in Turkey. Asian Pac J Cancer Prev. 2014;15(15):6263-6267.
Crossref Google Scholar
16

Sun JM, Ahn YC, Choi EK, et al. Phase Ⅲ trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol. 2013;24(8):2088-2092.
Crossref Google Scholar
17

Huncharek M, McGarry R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist. 2004;9(6):665-672.
Crossref Google Scholar
18

Pijls-Johannesma MC, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev. 2005;2004(1):CD004700.
Crossref Google Scholar
19

De Ruysscher D, Lueza B, Le Péchoux C, et al. RTT-SCLC Collaborative Group. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol. 2016;27(10):1818-1828.
Crossref Google Scholar
20

Simone CB 2nd, Bogart JA, Cabrera AR, et al. Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2020;10(3):158-173.
Crossref Google Scholar
21

Chun SG, Simone CB 2nd, Amini A, et al. American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020. J Thorac Oncol. 2021;16(1):66-75.
Crossref Google Scholar
22

Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061-2067.
Crossref Google Scholar
23

McMurdo ME, Roberts H, Parker S, et al. Comprehensive Clinical Research Network. Improving recruitment of older people to research through good practice. Age Ageing. 2011;40(6):659-665.
Crossref Google Scholar
24

Pallis AG, Shepherd FA, Lacombe D, Gridelli C. Treatment of small-cell lung cancer in elderly patients. Cancer. 2010;116(5):1192-2000.
Crossref Google Scholar
25

Bogart JA, Waqar SN, Mix MD. Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer. J Clin Oncol. 2022;40(6):661-670.
Crossref Google Scholar
Precision Radiation Oncology
Volume 8 Issue 1,
May 2024
Pages 14-21
DOI: 10.1002/pro6.1223
Cite this article:
Zhao H, Qi Y, Zhang L, et al. Thoracic radiotherapy timing and prognostic factors in elderly patients with limited-stage small cell lung cancer. Precision Radiation Oncology, 2024, 8(1): 14-21. https://doi.org/10.1002/pro6.1223

116

Views

1

Crossref

0

Scopus

Altmetrics
Received: 22 December 2023
Revised: 23 January 2024
Accepted: 17 February 2024
Published: 14 March 2024
© 2024 The Authors.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Return